<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="alk-nbs" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">alk-nbs</book-part-id>
      <title-group>
        <title>
<italic toggle="yes">ALK</italic>-Related Neuroblastic Tumor Susceptibility</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Greengard</surname>
            <given-names>Emily G</given-names>
          </name>
          <degrees>MD</degrees>
          <email>emilyg@umn.edu</email>
          <aff>University of Minnesota Masonic Children&#x02019;s Hospital<break/>Minneapolis, Minnesota</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Park</surname>
            <given-names>Julie R</given-names>
          </name>
          <degrees>MD</degrees>
          <email>julie.park@seattlechildrens.org</email>
          <aff>Seattle Children&#x02019;s Hospital<break/>Seattle, Washington</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2010-01-05" date-type="created">
          <day>5</day>
          <month>1</month>
          <year>2010</year>
        </date>
        <date iso-8601-date="2015-04-09" date-type="updated">
          <day>9</day>
          <month>4</month>
          <year>2015</year>
        </date>
        <date iso-8601-date="2013-05-09" date-type="revised">
          <day>9</day>
          <month>5</month>
          <year>2013</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="ipa" document-type="chapter">
<italic toggle="yes">AIP</italic>-Related Familial Isolated Pituitary Adenomas</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="iahsp" document-type="chapter">
<italic toggle="yes">ALS2</italic>-Related Disorders</related-object>
      <abstract id="alk-nbs.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p><italic toggle="yes">ALK-</italic>related neuroblastic tumor susceptibility results from heterozygosity for a germline <italic toggle="yes">ALK</italic> activating pathogenic variant in the tyrosine kinase domain that predisposes to neuroblastic tumors. The spectrum of neuroblastic tumors includes neuroblastoma, ganglioneuroblastoma, and ganglioneuroma. Neuroblastoma is a more malignant tumor and ganglioneuroma a more benign tumor. Depending on the histologic findings ganglioneuroblastoma can behave in a more aggressive fashion, like neuroblastoma, or in a benign fashion, like ganglioneuroma. At present there are no data regarding the lifetime risk to an individual with a germline <italic toggle="yes">ALK</italic> pathogenic variant of developing a neuroblastic tumor. Preliminary data from the ten reported families with <italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility suggest that the overall penetrance is around 57% with the risk for neuroblastic tumor development highest in infancy and decreasing by late childhood.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p><italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility is established by identification of a heterozygous germline <italic toggle="yes">ALK</italic> activating pathogenic variant in the tyrosine kinase domain that is known or suspected to cause altered kinase function.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Children who develop neuroblastic tumors should be evaluated and treated by a pediatric oncologist at a pediatric cancer center. Treatment for individuals with neuroblastoma and ganglioneuroblastoma who have a germline <italic toggle="yes">ALK</italic> activating pathogenic variant is the same standard risk-stratified therapy used to treat all neuroblastoma. Ganglioneuromas are typically removed by surgical resection and require no further therapy.</p>
          <p>
            <italic toggle="yes">Surveillance:</italic>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><italic toggle="yes">Asymptomatic children</italic>. Because no data are available as yet on the effect of screening in families with a germline <italic toggle="yes">ALK</italic> activating pathogenic variant and because tumor surveillance at the population level does not improve neuroblastoma outcome, there is currently no consensus on the proper frequency or type of tumor surveillance for asymptomatic children with a germline <italic toggle="yes">ALK</italic> activating pathogenic variant. In the absence of published guidelines, some healthcare providers perform the noninvasive measures of physical examination, abdominal ultrasound examination, and measurement of urine catecholamine metabolite levels every 1-2 months in infants age &#x02264;12 months and every 3-4 months in children age &#x02264;10 years; however, less frequent intervals may also be appropriate.</p>
            </list-item>
            <list-item>
              <p><italic toggle="yes">After successful treatment of a neuroblastic tumor.</italic> Screening for neuroblastoma should continue since children with <italic toggle="yes">ALK</italic>-related neuroblastoma are at risk of developing multiple primary tumors. Although no consensus exists, some recommend screening until age six years.</p>
            </list-item>
          </list>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> It is appropriate to test relatives at risk (i.e., sibs who are younger than age ten years at the time of diagnosis of the proband, as well as sibs born subsequently) for the <italic toggle="yes">ALK</italic> pathogenic variant found in the proband to identify those for whom early detection of neuroblastoma and initiation of therapy would likely improve quality of life and possibly affect outcome (if therapy is started prior to end organ damage).</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p><italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility is inherited in an autosomal dominant manner, with incomplete penetrance. Some (not all) individuals diagnosed with <italic toggle="yes">ALK</italic>-related neuroblastic susceptibility have an affected parent who may have had any one of the three neuroblastic tumor types. Although d<italic toggle="yes">e novo</italic> germline pathogenic variants have been reported, the proportion of individuals with a <italic toggle="yes">de novo</italic> pathogenic variant is unknown. Each child of an individual with <italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility has a 50% chance of inheriting the <italic toggle="yes">ALK</italic> pathogenic variant; however, the likelihood that a child who inherits the <italic toggle="yes">ALK</italic> pathogenic variant will develop a neuroblastic tumor is unknown. Prenatal testing for pregnancies at increased risk is possible; however, requests for prenatal testing for conditions which (like <italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility) do not affect intellect and have some treatment available are not common.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="alk-nbs.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="alk-nbs.Tc" position="anchor" orientation="portrait">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_alk-nbs.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">ALK</italic>-Related Neuroblastic Tumor Susceptibility: Included Disorders&#x000a0;<sup>1</sup></th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_alk-nbs.Tc_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Neuroblastoma</p>
                    </list-item>
                    <list-item>
                      <p>Ganglioneuroblastoma</p>
                    </list-item>
                    <list-item>
                      <p>Ganglioneuroma</p>
                    </list-item>
                  </list>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn id="alk-nbs.TF.c.1">
              <label>1. </label>
              <p>Forms of the disorders associated with genes other than <italic toggle="yes">ALK</italic> are not addressed in this <italic toggle="yes">GeneReview</italic>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="alk-nbs.Diagnosis">
        <title>Diagnosis</title>
        <sec id="alk-nbs.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p><italic toggle="yes">ALK-</italic>related neuroblastic tumor susceptibility should be suspected in an individual with:</p>
          <list list-type="bullet">
            <list-item>
              <p>A neuroblastic tumor including neuroblastoma, ganglioneuroblastoma, or ganglioneuroma;</p>
            </list-item>
            <list-item>
              <p>Multiple primary neuroblastic tumors that arise either synchronously or metachronously;</p>
            </list-item>
            <list-item>
              <p>A family history of one or more relatives with one of these three neuroblastic tumors [<xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>]. Note: Both benign and malignant tumors can occur in the same family.</p>
            </list-item>
          </list>
        </sec>
        <sec id="alk-nbs.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p><italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility is established by identification of a heterozygous germline <italic toggle="yes">ALK</italic> activating pathogenic variant in the tyrosine kinase domain that is known or suspected to cause altered kinase function (see <xref ref-type="table" rid="alk-nbs.T.molecular_genetic_testing_used">Table 1</xref>).</p>
          <p>Written guidelines for selection of individuals with a neuroblastic tumor to be tested for germline <italic toggle="yes">ALK</italic> pathogenic variants are under development, and no consensus opinion currently exists.</p>
          <p>Considerations for testing for germline <italic toggle="yes">ALK</italic> pathogenic variants include the following strong and moderate recommendations [<xref ref-type="bibr" rid="alk-nbs.REF.bourdeaut.2012.291">Bourdeaut et al 2012</xref>].</p>
          <p><bold>Strong recommendations</bold> regarding testing for germline <italic toggle="yes">ALK</italic> pathogenic variants:</p>
          <list list-type="bullet">
            <list-item>
              <p>All children with documented somatic <italic toggle="yes">ALK</italic> pathogenic variants within a neuroblastic tumor</p>
            </list-item>
            <list-item>
              <p>An individual with a neuroblastic tumor* who has at least one first-degree relative with a neuroblastic tumor*Note: Germline <italic toggle="yes">ALK</italic> pathogenic variants are equally likely to be identified in individuals with any of the three neuroblastic tumor types and with any stage of malignant neuroblastoma [<xref ref-type="bibr" rid="alk-nbs.REF.liu.2012.325">Liu &#x00026; Thiele 2012</xref>].</p>
            </list-item>
            <list-item>
              <p>An individual with a neuroblastic tumor and a family history of neuroblastic tumors that are not a manifestation of a neural crest disorder such as <related-object link-type="booklink" source-id="gene" document-id="hirschsprung-ov" document-type="chapter">Hirschsprung disease</related-object> or <related-object link-type="booklink" source-id="gene" document-id="ondine" document-type="chapter">central hypoventilation syndrome</related-object>, which may suggest mutation of <italic toggle="yes">PHOX2B</italic> [<xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>]. (See <xref ref-type="sec" rid="alk-nbs.Differential_Diagnosis">Differential Diagnosis</xref>.)</p>
            </list-item>
          </list>
          <p><bold>Moderate recommendation</bold> regarding testing for germline <italic toggle="yes">ALK</italic> pathogenic variants:</p>
          <list list-type="bullet">
            <list-item>
              <p>A simplex case (i.e., a single occurrence in a family) with bilateral neuroblastoma or multifocal primary neuroblastic tumors [<xref ref-type="bibr" rid="alk-nbs.REF.bourdeaut.2012.291">Bourdeaut et al 2012</xref>]</p>
            </list-item>
          </list>
          <p><bold>No recommendation for testing</bold> for germline <italic toggle="yes">ALK</italic> pathogenic variants:</p>
          <list list-type="bullet">
            <list-item>
              <p>An individual with a neuroblastic tumor and distant relatives (&#x02265;2<sup>nd</sup> degree) with a history of neuroblastic tumors, as such an individual is unlikely to have a germline <italic toggle="yes">ALK</italic> pathogenic variant [<xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>]</p>
            </list-item>
          </list>
          <p><bold>Considerations for testing for somatic <italic toggle="yes">ALK</italic> pathogenic variants</bold>. Some institutions are currently screening tumors of all children with neuroblastoma and others are screening tumors at the time of recurrence or progression, primarily for potential for <italic toggle="yes">ALK</italic>-directed therapy (see Molecular Genetics, <xref ref-type="sec" rid="alk-nbs.Cancer_and_Benign_Tumors">Cancer and Benign Tumors</xref>) rather than identifying those at increased risk for having a germline <italic toggle="yes">ALK</italic> pathogenic variant.</p>
          <p>The approach to molecular testing for a germline <italic toggle="yes">ALK</italic> pathogenic variant is sequence analysis to detect heterozygous germline <italic toggle="yes">ALK</italic> activating pathogenic variants in the tyrosine kinase domain that are known or suspected to cause altered kinase function.</p>
          <table-wrap id="alk-nbs.T.molecular_genetic_testing_used" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in <italic toggle="yes">ALK</italic>-Related Neuroblastic Tumor Susceptibility</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_1_2">Test Method</th>
                  <th id="hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_1_3" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Proportion of Probands with a Germline Activating Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
                <tr>
                  <th headers="hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_1_3" id="hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Familial&#x000a0;<sup>3</sup></th>
                  <th headers="hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_1_3" id="hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Simplex&#x000a0;<sup>4</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">ALK</italic>
                  </td>
                  <td headers="hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>5,&#x000a0;6</sup></td>
                  <td headers="hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_1_3 hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">80%&#x000a0;<sup>7,&#x000a0;8,&#x000a0;9,&#x000a0;10</sup></td>
                  <td headers="hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_1_3 hd_h_alk-nbs.T.molecular_genetic_testing_used_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Rare&#x000a0;<sup>9,&#x000a0;10</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="alk-nbs.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="alk-nbs" object-id="alk-nbs.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="alk-nbs.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="alk-nbs.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="alk-nbs.TF.1.3">
                <label>3. </label>
                <p>Familial <italic toggle="yes">=</italic> neuroblastoma in a proband plus a neuroblastic tumor (neuroblastoma, ganglioneuroblastoma, or ganglioneuroma) in a minimum of one first-degree relative</p>
              </fn>
              <fn id="alk-nbs.TF.1.4">
                <label>4. </label>
                <p>Simplex = neuroblastoma in a single individual in a family</p>
              </fn>
              <fn id="alk-nbs.TF.1.5">
                <label>5. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="alk-nbs.TF.1.6">
                <label>6. </label>
                <p>Some laboratories may offer sequence analysis of select exons as all reported <italic toggle="yes">ALK</italic> pathogenic variants are located in the tyrosine kinase domain encoded by exons 21-28 [<xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>].</p>
              </fn>
              <fn id="alk-nbs.TF.1.7">
                <label>7. </label>
                <p>
                  <xref ref-type="bibr" rid="alk-nbs.REF.liu.2012.325">Liu &#x00026; Thiele [2012]</xref>
                </p>
              </fn>
              <fn id="alk-nbs.TF.1.8">
                <label>8. </label>
                <p>In families with two or more first-degree relatives with neuroblastoma, the incidence of germline <italic toggle="yes">ALK</italic> pathogenic variants is high. In families in which two second-degree or more distant relatives have neuroblastoma, the incidence of germline <italic toggle="yes">ALK</italic> pathogenic variants is much lower [<xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>].</p>
              </fn>
              <fn id="alk-nbs.TF.1.9">
                <label>9. </label>
                <p>Somatic <italic toggle="yes">ALK</italic> activating pathogenic variants, which may be found in 7%-8% of sporadic neuroblastoma tumors, are rarely associated with germline <italic toggle="yes">ALK</italic> pathogenic variants [<xref ref-type="bibr" rid="alk-nbs.REF.liu.2012.325">Liu &#x00026; Thiele 2012</xref>]. In 167 tumors tested from simplex cases with high-risk neuroblastomas, <xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al [2008]</xref> found that 14 had somatic <italic toggle="yes">ALK</italic> missense variants that were predicted to be activating. Of these 14 individuals with somatic <italic toggle="yes">ALK</italic> missense variants, germline DNA was available on nine. In one of those nine individuals the <italic toggle="yes">ALK</italic> pathogenic variant, <xref ref-type="table" rid="alk-nbs.T.selected_alk_pathogenic_germli">p.Ile1250Thr</xref>, was identified in both germline and tumor DNA.</p>
              </fn>
              <fn id="alk-nbs.TF.1.10">
                <label>10. </label>
                <p>The <italic toggle="yes">ALK</italic> pathogenic variants (<xref ref-type="table" rid="alk-nbs.T.selected_alk_pathogenic_germli">p.Phe1174Val</xref> and <xref ref-type="table" rid="alk-nbs.T.selected_alk_pathogenic_germli">p.Phe1245Val</xref>) identified in the germline in two unrelated children with congenital neuroblastoma, severe developmental delay, and structural brain stem abnormalities have been reported as somatic pathogenic variants in neuroblastoma tumors but not in the germline of phenotypically normal individuals with neuroblastoma [<xref ref-type="bibr" rid="alk-nbs.REF.de_pontual.2011.272">de Pontual et al 2011</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="alk-nbs.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="alk-nbs.Clinical_Description">
          <title>Clinical Description</title>
          <p>Individuals with <italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility (i.e., who are heterozygous for a germline <italic toggle="yes">ALK</italic> activating pathogenic variant) are at risk of developing a spectrum of neuroblastic tumors that includes neuroblastoma, ganglioneuroblastoma, and ganglioneuroma. Within this spectrum, neuroblastoma represents a more malignant tumor and ganglioneuroma a more benign tumor. The three neuroblastic tumor types are defined histologically. Depending on the histologic findings, ganglioneuroblastoma can behave in a benign fashion, like ganglioneuroma, or in a more aggressive fashion, like neuroblastoma.</p>
          <p>There are no data at present regarding the percentage of individuals with a germline <italic toggle="yes">ALK</italic> pathogenic variant who will develop a neuroblastic tumor in their lifetime.</p>
          <p>Data from the ten reported families with <italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility suggest that the overall penetrance of this cancer predisposition syndrome is around 57% [<xref ref-type="bibr" rid="alk-nbs.REF.eng.2008.883">Eng 2008</xref>]. These data remain preliminary, as the numbers are small.</p>
          <p>Risk for neuroblastic tumor development is highest in infancy and decreases by late childhood. Individuals with familial neuroblastoma tend to develop tumors at a younger age (average 9 months) than those without familial predisposition (age 2-3 years) [<xref ref-type="bibr" rid="alk-nbs.REF.park.2008.97">Park et al 2008</xref>].</p>
          <p><bold>Multiple primary tumors.</bold> Individuals with familial neuroblastoma also have a higher than average incidence of multiple primary tumors [<xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>, <xref ref-type="bibr" rid="alk-nbs.REF.park.2008.97">Park et al 2008</xref>]. The multiple primary tumors may be bilateral adrenal tumors or multiple primary extra-adrenal tumors arising at sites of sympathetic ganglions. The tumors can occur either synchronously or metachronously [<xref ref-type="bibr" rid="alk-nbs.REF.bourdeaut.2012.291">Bourdeaut et al 2012</xref>].</p>
          <p><bold>Outcome.</bold> Given the rarity of familial neuroblastic tumors, statistically significant long-term outcome data are not yet available for individuals with <italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility. Although long-term survivors of neuroblastoma who are heterozygous for an inherited germline <italic toggle="yes">ALK</italic> pathogenic variant have been reported [<xref ref-type="bibr" rid="alk-nbs.REF.car_n.2008.153">Car&#x000e9;n et al 2008</xref>], no prospective studies have evaluated the survival of persons with a germline <italic toggle="yes">ALK</italic> pathogenic variant compared to those with neuroblastoma not associated with a germline <italic toggle="yes">ALK</italic> pathogenic variant.</p>
          <p>Since neuroblastoma outcome is heavily dependent on biologic characteristics and stage of the tumor, it is likely that survival from a neuroblastic tumor depends more on tumor type (neuroblastoma having the poorest outcome), tumor stage, and appropriate medical intervention than on the presence or absence of a germline <italic toggle="yes">ALK</italic> activating pathogenic variant [<xref ref-type="bibr" rid="alk-nbs.REF.park.2008.97">Park et al 2008</xref>].</p>
        </sec>
        <sec id="alk-nbs.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Aside from the following three pathogenic variants, no associations between specific germline <italic toggle="yes">ALK</italic> pathogenic variants and risk of developing neuroblastoma or outcome of neuroblastoma have been established [<xref ref-type="bibr" rid="alk-nbs.REF.azarova.2011.267">Azarova et al 2011</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p><xref ref-type="table" rid="alk-nbs.T.selected_alk_pathogenic_germli">p.Arg1275Gln</xref>, found in approximately 45% of individuals with a germline <italic toggle="yes">ALK</italic> pathogenic variant [<xref ref-type="bibr" rid="alk-nbs.REF.wood.2009">Wood et al 2009</xref>], may be associated with somewhat decreased penetrance (40%).</p>
            </list-item>
            <list-item>
              <p><xref ref-type="table" rid="alk-nbs.T.selected_alk_pathogenic_germli">p.Gly1128Ala</xref>, reported as a germline <italic toggle="yes">ALK</italic> pathogenic variant in one large family, appeared to have lower penetrance: 40% of heterozygotes developed a neuroblastoma during childhood [<xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>]. Adult heterozygotes were healthy; no tumor types other than neuroblastoma were reported.</p>
            </list-item>
            <list-item>
              <p>p.Phe1174Leu.The one individual reported with this germline pathogenic variant experienced early lethality [<xref ref-type="bibr" rid="alk-nbs.REF.de_brouwer.2010.4353">De Brouwer et al 2010</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="alk-nbs.Penetrance">
          <title>Penetrance</title>
          <p>Penetrance is incomplete. Several asymptomatic adults who are obligate heterozygotes have been identified [<xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>, <xref ref-type="bibr" rid="alk-nbs.REF.bourdeaut.2012.291">Bourdeaut et al 2012</xref>]. In at least one family, a child with neuroblastoma inherited the <xref ref-type="table" rid="alk-nbs.T.selected_alk_pathogenic_germli">p.Arg1275Gln</xref> pathogenic variant from an unaffected father [<xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>].</p>
          <p>See also <xref ref-type="sec" rid="alk-nbs.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref> for information on penetrance.</p>
        </sec>
        <sec id="alk-nbs.Prevalence">
          <title>Prevalence</title>
          <p>About 1%-2% of probands with neuroblastoma have a close relative with neuroblastoma [<xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>].</p>
        </sec>
      </sec>
      <sec id="alk-nbs.Genetically_Related_Allelic_Diso">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><bold>Germline <italic toggle="yes">ALK</italic> pathogenic variants.</bold> The majority of individuals with a germline <italic toggle="yes">ALK</italic> pathogenic variant have no obvious phenotype other than predisposition to neuroblastoma. The exceptions are the pathogenic variants (<xref ref-type="table" rid="alk-nbs.T.selected_alk_pathogenic_germli">p.Phe1174Val</xref> and <xref ref-type="table" rid="alk-nbs.T.selected_alk_pathogenic_germli">p.Phe1245Val</xref>) identified in the germline in two unrelated children with congenital neuroblastoma, severe developmental delay, and structural brain stem abnormalities. Although these pathogenic variants have been reported as somatic mutations in neuroblastoma tumors, they have not been reported in the germline of phenotypically normal individuals with neuroblastoma [<xref ref-type="bibr" rid="alk-nbs.REF.de_pontual.2011.272">de Pontual et al 2011</xref>].</p>
        <p><bold>Sporadic tumors</bold> (including neuroblastoma) occurring as single tumors in the absence of any other findings of this syndrome frequently harbor somatic variants in <italic toggle="yes">ALK</italic> that are <bold>not</bold> present in the germline; thus, predisposition to these tumors is not heritable. For more details see Molecular Genetics, <xref ref-type="sec" rid="alk-nbs.Cancer_and_Benign_Tumors">Cancer and Benign Tumors</xref>.</p>
      </sec>
      <sec id="alk-nbs.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Germline pathogenic variants in <italic toggle="yes">ALK</italic> and <italic toggle="yes">PHOX2B</italic> are the etiologic agents for familial neuroblastoma susceptibility.</p>
        <list list-type="bullet">
          <list-item>
            <p>Heterozygous germline <italic toggle="yes">ALK</italic> pathogenic variants are the main cause of familial susceptibility to neuroblastoma in otherwise healthy individuals.</p>
          </list-item>
          <list-item>
            <p>Heterozygous germline <italic toggle="yes">PHOX2B</italic> pathogenic variants account for the remainder of families, most of whom also have disorders of neural crest development (see <bold><italic toggle="yes">PHOX2B</italic></bold>) [<xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>, <xref ref-type="bibr" rid="alk-nbs.REF.azarova.2011.267">Azarova et al 2011</xref>].</p>
          </list-item>
        </list>
        <p><bold><italic toggle="yes">PHOX2B</italic>.</bold> Germline <italic toggle="yes">PHOX2B</italic> pathogenic variants most commonly occur in association with familial neuroblastoma and disorders of neural crest development, such as <related-object link-type="booklink" source-id="gene" document-id="hirschsprung-ov" document-type="chapter">Hirschsprung disease</related-object>, decreased esophageal motility, or <related-object link-type="booklink" source-id="gene" document-id="ondine" document-type="chapter">congenital central hypoventilation syndrome</related-object>. Persons with a heterozygous germline <italic toggle="yes">PHOX2B</italic> pathogenic variant may also have dysmorphic features, including downslanting palpebral fissures, small nose, triangular shaped mouth, or low-set, posteriorly rotated ears.</p>
        <p>If the family history or medical history of the individual is positive for disorders of neural crest development or the individual has characteristic facial features, it is likely that a germline <italic toggle="yes">PHOX2B</italic> pathogenic variant (rather than a germline <italic toggle="yes">ALK</italic> variant) is causative [<xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>].</p>
        <p><bold><italic toggle="yes">KIF1B.</italic></bold> A germline <italic toggle="yes">KIF1B</italic> pathogenic variant has been reported in a three-generation family with a predisposition to neuronal and non-neuronal tumors. Of the three individuals in the family who developed tumors, one had bilateral pheochromocytomas, a ganglioneuroma, and a leiomyosarcoma; one had bilateral pheochromocytoma; and one had adenocarcinoma of the lung [<xref ref-type="bibr" rid="alk-nbs.REF.yeh.2008.279">Yeh et al 2008</xref>]. None of the individuals with a germline <italic toggle="yes">KIF1B</italic> pathogenic variant had neuroblastoma.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="nf1" document-type="chapter"><bold>Neurofibromatosis 1</bold></related-object>
<bold>(NF1).</bold> Compared with the general population, children with NFI are at increased risk of developing malignancies, including neuroblastoma, rhabdomyosarcoma, and peripheral nerve sheath tumors [<xref ref-type="bibr" rid="alk-nbs.REF.brems.2009.508">Brems et al 2009</xref>]. Features of NF1 include multiple caf&#x000e9;-au-lait macules, axillary and inguinal freckling, multiple cutaneous neurofibromas, and iris Lisch nodules. Learning disabilities are present in at least 50% of individuals with NF1. NF1 is inherited in an autosomal dominant manner. Half of affected individuals have NF1 as the result of a <italic toggle="yes">de novo NF1</italic> pathogenic variant.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="bws" document-type="chapter"><bold>Beckwith-Weidemann syndrome</bold></related-object>
<bold>(BWS).</bold> Persons with BWS are at increased risk for embryonal malignancies, including neuroblastoma (relative risk of 197 compared to the general population, as described by <xref ref-type="bibr" rid="alk-nbs.REF.debaun.1998.398">DeBaun &#x00026; Tucker [1998]</xref>), Wilms tumor, hepatoblastoma, and rhabdomyosarcoma. In addition, BWS is a growth disorder characterized by macrosomia, macroglossia, visceromegaly, omphalocele, neonatal hypoglycemia, ear creases/pits, adrenocortical cytomegaly, and renal abnormalities (e.g., medullary dysplasia, nephrocalcinosis, medullary sponge kidney, and nephromegaly). Hemihyperplasia may affect segmental regions of the body or selected organs and tissues. Of these physical findings, only the hemihypertrophy is independently associated with increased tumor risk.</p>
        <p>BWS is associated with abnormal regulation of gene transcription in the imprinted domain on chromosome 11p15.5, which can be caused by different genetic mechanisms: abnormal methylation of one of two differently methylated regions (DMRs), paternal uniparental disomy, or mutation of <italic toggle="yes">CDKN1C</italic>. BWS usually occurs in simplex cases, but can also be inherited in an autosomal dominant manner.</p>
      </sec>
      <sec id="alk-nbs.Management_1">
        <title>Management</title>
        <sec id="alk-nbs.Evaluations_Following_Initial_Di">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with <italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility, the following evaluations are recommended based on the author&#x02019;s personal experience as no guidelines have been established for initial evaluation of individuals diagnosed with a germline <italic toggle="yes">ALK</italic> pathogenic variant.</p>
          <list list-type="bullet">
            <list-item>
              <p>Physical examination to assess for clinical manifestations of neuroblastic tumors such as an abdominal mass, Horner syndrome, and/ or cutaneous lesions</p>
            </list-item>
            <list-item>
              <p>Radiograph of the chest radiograph and ultrasound examination of the abdomen, the most common sites for neuroblastic tumor development</p>
            </list-item>
            <list-item>
              <p>Measurement of urine cathecholamines, as homovanillic acid and vanillylmendelic acid may be elevated in the presence of a neuroblastic tumor</p>
            </list-item>
            <list-item>
              <p>Medical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="alk-nbs.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Children who develop neuroblastic tumors (neuroblastomas, ganglioneuroblastoma, or ganglioneuroma) should be evaluated and treated by a pediatric oncologist at a pediatric cancer center.</p>
          <p><bold>Neuroblastoma and ganglioneuroblastoma.</bold> The treatment for individuals with a neuroblastic tumor who have a germline <italic toggle="yes">ALK</italic> activating pathogenic variant is the same standard risk-stratified therapy used to treat all neuroblastic tumors. Clinical trials are ongoing to study the efficacy of <italic toggle="yes">ALK</italic>-targeted therapy in the setting of relapsed and refractory neuroblastoma and ganglioneuroblastoma (see <xref ref-type="sec" rid="alk-nbs.Therapies_Under_Investigation">Therapies Under Investigation</xref>).</p>
          <p>The management guidelines for neuroblastoma or ganglioneuroblastoma are complex [<xref ref-type="bibr" rid="alk-nbs.REF.irwin.2015.225">Irwin &#x00026; Park 2015</xref>]</p>
          <list list-type="bullet">
            <list-item>
              <p>Depending on the age of the affected individual, stage of the tumor, and biologic characteristics of the tumor, treatment may involve observation or surgical resection.</p>
            </list-item>
            <list-item>
              <p>Tumors with risk for metastatic spread or those that have already metastasized require chemotherapy and sometimes radiation therapy, stem cell transplantation, and immunotherapy.</p>
            </list-item>
          </list>
          <p><bold>Ganglioneuromas</bold> are typically removed by surgical resection and require no further therapy.</p>
        </sec>
        <sec id="alk-nbs.Surveillance">
          <title>Surveillance</title>
          <p><bold>Asymptomatic children at risk.</bold> Large-scale, population-based studies in Japan, Europe, Canada, and the US that screened healthy infants with urinary catecholamines to identify neuroblastomas found no improvement in survival in children diagnosed before symptoms occurred [<xref ref-type="bibr" rid="alk-nbs.REF.schilling.2002.1047">Schilling et al 2002</xref>, <xref ref-type="bibr" rid="alk-nbs.REF.woods.2002.1041">Woods et al 2002</xref>].</p>
          <p>Because no data are available as yet on the effect of screening in families with a germline <italic toggle="yes">ALK</italic> activating pathogenic variant and because tumor surveillance at the population level does not improve neuroblastoma outcome, there is currently no consensus on the proper frequency or type of tumor surveillance for individuals with a germline <italic toggle="yes">ALK</italic> activating pathogenic variant. In the absence of published guidelines, the noninvasive measures of physical examination, abdominal ultrasound examination, and measurement of urine catecholamine metabolite levels have been performed on the following schedule; less frequent intervals may also be appropriate.</p>
          <list list-type="bullet">
            <list-item>
              <p>Every 1-2 months in infants age &#x02264;12 months</p>
            </list-item>
            <list-item>
              <p>Every 3-4 months in children age &#x02264;10 years</p>
            </list-item>
          </list>
          <p><bold>After successful treatment of a neuroblastic tumor</bold>, screening for neuroblastic tumors should continue since children with <italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility are at risk of developing multiple primary tumors. Although no consensus exists, some recommend screening until age six years [<xref ref-type="bibr" rid="alk-nbs.REF.bourdeaut.2012.291">Bourdeaut et al 2012</xref>].</p>
        </sec>
        <sec id="alk-nbs.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>There is currently no evidence that individuals with <italic toggle="yes">ALK</italic>-related neuroblastoma tumor susceptibility have increased sensitivity to chemotherapeutic agents or radiation therapy; thus, medical and surgical management of tumors should be the same as for the general population.</p>
        </sec>
        <sec id="alk-nbs.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to test relatives at risk* for the <italic toggle="yes">ALK</italic> pathogenic variant found in the proband to identify those at high risk for neuroblastoma, for whom early detection of neuroblastoma and initiation of therapy would likely improve quality of life and may affect outcome (if therapy is started prior to end organ damage).</p>
          <p>*Sibs who are younger than age ten years at the time of diagnosis of the proband, as well as sibs born subsequently.</p>
          <p>See <xref ref-type="sec" rid="alk-nbs.Related_Genetic_Counseling_Issue">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="alk-nbs.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Oral preparations of small molecule inhibitors targeting the ALK tyrosine kinase domain (e.g., crizotinib, ceritinib) have shown efficacy and minimal toxicity in children with <italic toggle="yes">ALK</italic> translocated tumors other than neuroblastoma.</p>
          <p>Of affected individuals with refractory/relapsed neuroblastoma, response has only been identified in those with tumors resulting from germline <italic toggle="yes">ALK</italic> pathogenic variants, including a complete response in at least one individual [<xref ref-type="bibr" rid="alk-nbs.REF.moss_.2012">Moss&#x000e9; et al 2012</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="alk-nbs.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="alk-nbs.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p><italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility is inherited in an autosomal dominant manner, with incomplete penetrance [<xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>].</p>
        </sec>
        <sec id="alk-nbs.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Some (not all) individuals diagnosed with <italic toggle="yes">ALK</italic>-related neuroblastic susceptibility have an affected parent who may have had any one of the three associated tumor types (neuroblastoma, ganglioneuroma, or ganglioneuroblastoma). Because of incomplete penetrance, a parent may have a germline <italic toggle="yes">ALK</italic> activating pathogenic variant without having developed a neuroblastic tumor [<xref ref-type="bibr" rid="alk-nbs.REF.janoueixlerosey.2008.967">Janoueix-Lerosey et al 2008</xref>, <xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>].</p>
            </list-item>
            <list-item>
              <p>As yet, no tumor types other than neuroblastoma, ganglioneuroma, or ganglioneuroblastoma have been reported to be associated with germline <italic toggle="yes">ALK</italic> activating pathogenic variants and no data regarding the cancer risk for adults with a germline <italic toggle="yes">ALK</italic> activating pathogenic variant have been published.</p>
            </list-item>
            <list-item>
              <p>Parents of a proband should be offered molecular genetic testing for the germline <italic toggle="yes">ALK</italic> activating pathogenic variant identified in their child.</p>
            </list-item>
            <list-item>
              <p>A proband with <italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility may have the disorder as the result of a <italic toggle="yes">de novo</italic> germline <italic toggle="yes">ALK</italic> activating pathogenic variant. Although d<italic toggle="yes">e novo</italic> germline pathogenic variants have been reported, the proportion of <italic toggle="yes">de novo</italic> pathogenic variants is unknown.</p>
            </list-item>
            <list-item>
              <p>If the germline <italic toggle="yes">ALK</italic> activating pathogenic variant found in the proband cannot be detected in the DNA of either parent, two possible explanations are germline mosaicism in a parent or a <italic toggle="yes">de novo</italic> pathogenic variant in the proband. Although no instances of germline mosaicism have been reported to date, it remains a possibility.</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> germline <italic toggle="yes">ALK</italic> activating pathogenic variant include testing for the <italic toggle="yes">ALK</italic> pathogenic variant detected in the proband.</p>
            </list-item>
            <list-item>
              <p>The family history of some individuals diagnosed with <italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility may appear to be negative because of incomplete penetrance or failure to recognize the disorder in family members. Therefore, an apparently negative family history cannot be confirmed unless molecular genetic testing has confirmed that neither of the parents has the germline <italic toggle="yes">ALK</italic> pathogenic variant identified in the proband.</p>
            </list-item>
          </list>
          <p>Note: If the parent is the individual in whom the pathogenic variant first occurred s/he may have somatic mosaicism for the variant and may never have developed neuroblastoma or a related tumor, although this has not been reported for <italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility.</p>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to sibs for <italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility depends on the genetic status of the proband&#x02019;s parents.</p>
            </list-item>
            <list-item>
              <p>If a parent of the proband is affected or has a germline <italic toggle="yes">ALK</italic> activating pathogenic variant, the risk to the sibs of inheriting the pathogenic variant is 50%. Because <italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility is a recently described condition, the likelihood that a sib who inherits the <italic toggle="yes">ALK</italic> pathogenic variant will develop a neuroblastic tumor is not yet known.</p>
            </list-item>
            <list-item>
              <p>The sibs of a proband with clinically unaffected parents whose <italic toggle="yes">ALK</italic> variant status is unknown are still at increased risk (for the disorder) because of incomplete penetrance in a parent.</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">ALK</italic> pathogenic variant found in the proband cannot be detected in the DNA of either parent, the risk to sibs is low, but greater than that of the general population because of the theoretic possibility of germline mosaicism. Note: Sibs of all probands with neuroblastoma have an increased chance of developing neuroblastoma themselves, with a standardized incidence ratio of 9.7 compared to the general population [<xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>]. This increased risk is likely due in part to the possibility of inherited germline <italic toggle="yes">ALK</italic> pathogenic variants in some children with neuroblastoma.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Each child of an individual with <italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility has a 50% chance of inheriting the <italic toggle="yes">ALK</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>The likelihood that a child who inherits the <italic toggle="yes">ALK</italic> pathogenic variant will develop a neuroblastic tumor is unknown though the penetrance is high (57%) [<xref ref-type="bibr" rid="alk-nbs.REF.eng.2008.883">Eng 2008</xref>]) and the relative risk (compared to any child from the general population) of developing a neuroblastic tumor is substantial.</p>
            </list-item>
          </list>
          <p>
            <bold>Other family members</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to other family members depends on the status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>If a parent is affected or has a germline <italic toggle="yes">ALK</italic> activating pathogenic variant, his or her family members may be at risk for neuroblastoma or related tumors.</p>
            </list-item>
            <list-item>
              <p>Whether or not an individual is at risk for <italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility can be determined by pedigree analysis and molecular genetic testing.</p>
            </list-item>
          </list>
        </sec>
        <sec id="alk-nbs.Related_Genetic_Counseling_Issue">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="alk-nbs.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When neither parent of a proband with this autosomal dominant condition has the <italic toggle="yes">ALK</italic> pathogenic variant identified in the proband, it is likely that the proband has a <italic toggle="yes">de novo</italic> pathogenic variant. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p>
          <p><bold>Testing of at-risk asymptomatic relatives</bold> of individuals with <italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility is possible after molecular genetic testing has identified the specific germline <italic toggle="yes">ALK</italic> pathogenic variant in the family. Although molecular genetic testing can identify the presence of an <italic toggle="yes">ALK</italic> pathogenic variant, it cannot predict whether neuroblastoma, ganglioneuroma, or ganglioneuroblastoma will develop.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, have a germline <italic toggle="yes">ALK</italic> activating pathogenic variant, or are at risk of having a germline <italic toggle="yes">ALK</italic> activating pathogenic variant.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="alk-nbs.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the germline <italic toggle="yes">ALK</italic> activating pathogenic variant has been identified in an affected family member, prenatal testing for pregnancies at increased risk may be available from a clinical laboratory that offers either testing of this gene or custom prenatal testing.</p>
          <p>Requests for prenatal testing for conditions which (like <italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility) do not affect intellect and have some treatment available are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
          <p>Note: Although molecular genetic testing can identify the presence of a germline <italic toggle="yes">ALK</italic> activating pathogenic variant, it cannot predict whether neuroblastoma will develop.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which a germline <italic toggle="yes">ALK</italic> activating pathogenic variant has been identified.</p>
        </sec>
      </sec>
      <sec id="alk-nbs.Resources">
        <title>Resources</title>
      </sec>
      <sec id="alk-nbs.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="alk-nbs.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p><italic toggle="yes">ALK</italic> is predicted to function as an oncogene in the pathogenesis of neuroblastoma [<xref ref-type="bibr" rid="alk-nbs.REF.chen.2008.971">Chen et al 2008</xref>, <xref ref-type="bibr" rid="alk-nbs.REF.george.2008.975">George et al 2008</xref>, <xref ref-type="bibr" rid="alk-nbs.REF.janoueixlerosey.2008.967">Janoueix-Lerosey et al 2008</xref>, <xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>]. Somatic chromosomal translocations causing constitutive activation of <italic toggle="yes">ALK</italic> are known to mediate malignant transformation in other types of tumors such as non-small-cell lung cancer (<italic toggle="yes">ALK/EML4</italic> fusion protein) and anaplastic large-cell lymphoma (<italic toggle="yes">ALK/NPM1</italic>) [<xref ref-type="bibr" rid="alk-nbs.REF.palmer.2009.345">Palmer et al 2009</xref>].</p>
          <p>In <italic toggle="yes">ALK</italic>-related neuroblastoma, both germline and somatic pathogenic variants are found exclusively within the tyrosine kinase domain of <italic toggle="yes">ALK</italic>. These pathogenic variants lead to constitutive phosphorylation and activation of the ALK protein. Somatic amplification of <italic toggle="yes">ALK</italic> on chromosome 2p23 has also been identified in a subset of sporadic neuroblastomas with unfavorable biologic characteristics and aggressive clinical course.</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">ALK</italic> comprises 29 coding exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="alk-nbs" object-id="alk-nbs.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Pathogenic allelic variants.</bold> The vast majority (91%) of <italic toggle="yes">ALK</italic> pathogenic variants fall within the kinase domain [<xref ref-type="bibr" rid="alk-nbs.REF.chen.2008.971">Chen et al 2008</xref>]. Missense mutations in the tyrosine kinase domain of <italic toggle="yes">ALK</italic> are associated with <italic toggle="yes">ALK</italic>-related neuroblastic tumor susceptibility [<xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>].</p>
          <p>The variant <xref ref-type="table" rid="alk-nbs.T.selected_alk_pathogenic_germli">p.Arg1275Gln</xref>, the most commonly reported germline pathogenic variant, is found in approximately 45% of individuals with a germline pathogenic variant [<xref ref-type="bibr" rid="alk-nbs.REF.wood.2009">Wood et al 2009</xref>]; it is also the most common somatic pathogenic variant.</p>
          <table-wrap id="alk-nbs.T.selected_alk_pathogenic_germli" position="anchor" orientation="portrait">
            <label>Table 2. </label>
            <caption>
              <p>Selected <italic toggle="yes">ALK</italic> Pathogenic Germline Allelic Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_alk-nbs.T.selected_alk_pathogenic_germli_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                  <th id="hd_h_alk-nbs.T.selected_alk_pathogenic_germli_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                  <th id="hd_h_alk-nbs.T.selected_alk_pathogenic_germli_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_alk-nbs.T.selected_alk_pathogenic_germli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.3824G&#x0003e;A</td>
                  <td headers="hd_h_alk-nbs.T.selected_alk_pathogenic_germli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg1275Gln (most common)</td>
                  <td headers="hd_h_alk-nbs.T.selected_alk_pathogenic_germli_1_1_1_3" rowspan="8" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nucleotide/29029631">NM_004304.3</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/29029632">NP_004295.2</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_alk-nbs.T.selected_alk_pathogenic_germli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.3383G&#x0003e;C</td>
                  <td headers="hd_h_alk-nbs.T.selected_alk_pathogenic_germli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly1128Ala</td>
                </tr>
                <tr>
                  <td headers="hd_h_alk-nbs.T.selected_alk_pathogenic_germli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.3575G&#x0003e;C</td>
                  <td headers="hd_h_alk-nbs.T.selected_alk_pathogenic_germli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg1192Pro</td>
                </tr>
                <tr>
                  <td headers="hd_h_alk-nbs.T.selected_alk_pathogenic_germli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.3260C&#x0003e;T</td>
                  <td headers="hd_h_alk-nbs.T.selected_alk_pathogenic_germli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr1087Ile</td>
                </tr>
                <tr>
                  <td headers="hd_h_alk-nbs.T.selected_alk_pathogenic_germli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.3452C&#x0003e;T</td>
                  <td headers="hd_h_alk-nbs.T.selected_alk_pathogenic_germli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr1151Met&#x000a0;<sup>1</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_alk-nbs.T.selected_alk_pathogenic_germli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.3749T&#x0003e;C</td>
                  <td headers="hd_h_alk-nbs.T.selected_alk_pathogenic_germli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ile1250Thr&#x000a0;<sup>2</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_alk-nbs.T.selected_alk_pathogenic_germli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.3520T&#x0003e;G</td>
                  <td headers="hd_h_alk-nbs.T.selected_alk_pathogenic_germli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Phe1174Val&#x000a0;<sup>3</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_alk-nbs.T.selected_alk_pathogenic_germli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.3733T&#x0003e;G</td>
                  <td headers="hd_h_alk-nbs.T.selected_alk_pathogenic_germli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Phe1245Val&#x000a0;<sup>3</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="alk-nbs.TF.2.1">
                <label>1. </label>
                <p>
                  <xref ref-type="bibr" rid="alk-nbs.REF.george.2008.975">George et al [2008]</xref>
                </p>
              </fn>
              <fn id="alk-nbs.TF.2.2">
                <label>2. </label>
                <p>
                  <xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al [2008]</xref>
                </p>
              </fn>
              <fn id="alk-nbs.TF.2.3">
                <label>3. </label>
                <p>
                  <xref ref-type="bibr" rid="alk-nbs.REF.de_pontual.2011.272">de Pontual et al [2011]</xref>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold>
<italic toggle="yes">ALK</italic> encodes a 1620-amino acid protein that is a single chain receptor tyrosine kinase; its normal function is not known [<xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>]. Expression is restricted to the developing central and peripheral nervous system with a postulated role in regulation of neuronal differentiation.</p>
          <p><bold>Abnormal gene product.</bold> Pathogenic variants in the tyrosine kinase domain of <italic toggle="yes">ALK</italic> result in constitutive phosphorylation [<xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>] and are predicted with high probability to drive oncogenesis [<xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>]. Both <italic toggle="yes">ALK</italic> pathogenic variants and amplifications have been shown to have direct oncogenic effect, as evidenced by autophosphorylation of mutant strains and activation of downstream targets in neuroblastoma cell lines harboring <italic toggle="yes">ALK</italic> pathogenic variants and amplification [<xref ref-type="bibr" rid="alk-nbs.REF.janoueixlerosey.2008.967">Janoueix-Lerosey et al 2008</xref>, <xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>]. Tumors with aberrant <italic toggle="yes">ALK</italic> signaling display transforming potential in vivo, inducing soft agar colony formation in mutant cell lines, rapid tumor growth in nude mice, and increased apoptosis in response to small interfering or small-hairpin RNA targeted against <italic toggle="yes">ALK</italic> [<xref ref-type="bibr" rid="alk-nbs.REF.chen.2008.971">Chen et al 2008</xref>, <xref ref-type="bibr" rid="alk-nbs.REF.george.2008.975">George et al 2008</xref>, <xref ref-type="bibr" rid="alk-nbs.REF.park.2008.97">Park et al 2008</xref>].</p>
        </sec>
        <sec id="alk-nbs.Cancer_and_Benign_Tumors">
          <title>Cancer and Benign Tumors</title>
          <p>Fusion proteins resulting from somatic translocations involving <italic toggle="yes">ALK</italic> have been implicated in several types of cancer. In all these tumors, aberrant ALK signaling occurs as a result of a chromosomal translocation involving the <italic toggle="yes">ALK</italic> locus at 2p23. In contrast, germline and somatic <italic toggle="yes">ALK</italic> pathogenic variants have only been discovered in neuroblastoma.</p>
          <p><bold>Fusion proteins.</bold> Anaplastic large-cell lymphomas harbor a characteristic chromosome 2;5 translocation involving <italic toggle="yes">ALK</italic> and <italic toggle="yes">NPM1</italic> (encoding nucleophosmin), which may be referred to as <italic toggle="yes">ALK/NPM1</italic> [<xref ref-type="bibr" rid="alk-nbs.REF.morris.1994.1281">Morris et al 1994</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p><italic toggle="yes">ALK/EML4</italic> fusion transcripts are found in a subset of individuals with non-small-cell lung cancer, all of whom lack <italic toggle="yes">EGFR</italic> mutations [<xref ref-type="bibr" rid="alk-nbs.REF.soda.2007.561">Soda et al 2007</xref>].</p>
            </list-item>
            <list-item>
              <p><italic toggle="yes">ALK</italic> fusion proteins have also been described in inflammatory myofibroblastic tumors, diffuse large B-cell lymphomas, and squamous cell carcinomas of the esophagus [<xref ref-type="bibr" rid="alk-nbs.REF.palmer.2009.345">Palmer et al 2009</xref>].</p>
            </list-item>
          </list>
          <p><bold>Somatic <italic toggle="yes">ALK</italic> pathogenic variants.</bold> The frequency of somatic <italic toggle="yes">ALK</italic> pathogenic variants involving neuroblastoma tumor tissue is 6%-12% [Santani A &#x00026; Maris J, personal communication]. Disruption of normal <italic toggle="yes">ALK</italic> signaling is likely to play a critical role in neuroblastic tumor pathogenesis. Furthermore, it appears that patients whose tumor harbors a somatic <italic toggle="yes">ALK</italic> activating pathogenic variant or <italic toggle="yes">ALK</italic> amplification (i.e., &#x0003e;10 copies of <italic toggle="yes">ALK</italic>) have a poorer prognosis than patients with otherwise similar tumor stage and biology [<xref ref-type="bibr" rid="alk-nbs.REF.chen.2008.971">Chen et al 2008</xref>; <xref ref-type="bibr" rid="alk-nbs.REF.moss_.2008.930">Moss&#x000e9; et al 2008</xref>; <xref ref-type="bibr" rid="alk-nbs.REF.moss_.2013.472">Moss&#x000e9; et al 2013</xref>; Santani A &#x00026; Maris J, personal communication].</p>
          <p>Preclinical data suggest that responsiveness to crizotinib may depend on the presence or absence and specific type of somatic <italic toggle="yes">ALK</italic> pathogenic variant (i.e., in the tumor). Specifically, tumors with the somatic <italic toggle="yes">ALK</italic> pathogenic variants p.Phe1174Leu, p.Gly1128Ala, p.Met1166Arg, p.Phe1245Cys, p.Phe1245Val, and p.Tyr1278Ser are relatively crizotinib-resistant, whereas the p.Ile1170Asn, p.Ile1170Ser, p.Ile1171Asn, p.Leu1196Met, and p.Arg1275Gln variants are sensitive to crizotinib. The p.Arg1192Pro variant is intermediate in sensitivity [<xref ref-type="bibr" rid="alk-nbs.REF.moss_.2013.472">Moss&#x000e9; et al 2013</xref>]. Subsequent Phase II and III clinical trials for neuroblastoma will incorporate <italic toggle="yes">ALK</italic> molecular genetic testing for the tumors of all individuals enrolled in the trial.</p>
          <p>These data have been confirmed in other studies as well. For example, human neuroblastoma-derived cell lines harboring mutant proteins with the <xref ref-type="table" rid="alk-nbs.T.selected_alk_pathogenic_germli">p.Arg1275Gln</xref> substitution, the most common abnormal protein described in <italic toggle="yes">ALK</italic>-related neuroblastoma [<xref ref-type="bibr" rid="alk-nbs.REF.azarova.2011.267">Azarova et al 2011</xref>], were more sensitive to the small-molecule <italic toggle="yes">ALK</italic> inhibitor PF-02341066 than cell lines harboring proteins with the p.Phe1174Leu substitution or those without <italic toggle="yes">ALK</italic> aberrations [<xref ref-type="bibr" rid="alk-nbs.REF.wood.2009">Wood et al 2009</xref>]. The cell line most sensitive to pharmacologic inhibition harbors high-level amplification of <italic toggle="yes">ALK</italic> (wild-type sequence). Clinical correlation in individuals with neuroblastoma has yet to be determined [<xref ref-type="bibr" rid="alk-nbs.REF.wood.2009">Wood et al 2009</xref>].</p>
          <p>The variant p.Phe1174Leu, associated with amplification of the oncogene <italic toggle="yes">MYCN</italic>, is found as a somatic pathogenic variant in 30% of sporadic neuroblastoma tumors that harbor an <italic toggle="yes">ALK</italic> pathogenic variant [<xref ref-type="bibr" rid="alk-nbs.REF.carpenter.2012.391">Carpenter &#x00026; Moss&#x000e9; 2012</xref>]. Individuals with this pathogenic variant have a worse prognosis than individuals with <italic toggle="yes">MYCN</italic> amplification alone [<xref ref-type="bibr" rid="alk-nbs.REF.azarova.2011.267">Azarova et al 2011</xref>].</p>
        </sec>
      </sec>
      <sec id="alk-nbs.References">
        <title>References</title>
        <sec id="alk-nbs.Published_GuidelinesConsensus_St">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="alk-nbs.Published_GuidelinesConsensus_St.reflist0">
            <ref id="alk-nbs.REF1">
              <mixed-citation publication-type="webpage">American Society of Clinical Oncology. Policy statement update: genetic testing for cancer susceptibility. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://jco.ascopubs.org/content/28/5/893.long">online</ext-link>; registration or institutional access required. 2010. Accessed 6-11-15.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="alk-nbs.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="alk-nbs.Literature_Cited.reflist0">
            <ref id="alk-nbs.REF.azarova.2011.267">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Azarova</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gautam</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>George</surname>
                    <given-names>RE</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Emerging importance of ALK in neuroblastoma.</article-title>
                <source>Semin Cancer Biol.</source>
                <volume>21</volume>
                <fpage>267</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">21945349</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.bourdeaut.2012.291">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bourdeaut</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrand</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brugi&#x000e8;res</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hilbert</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribeiro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacroix</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000e9;nard</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Combaret</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michon</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valteau-Couanet</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Isidor</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rialland</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poir&#x000e9;e</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Defachelles</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peuchmaur</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schleiermacher</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pierron</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gauthier-Villars</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janoueix-Lerosey</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delattre</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <article-title>Comit&#x000e9; Neuroblastome of the Soci&#x000e9;t&#x000e9; Francaise de Canc&#x000e9;rologie. ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2012</year>
                <volume>20</volume>
                <fpage>291</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">22071890</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.brems.2009.508">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brems</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beert</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Ravel</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Legius</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1.</article-title>
                <source>Lancet Oncol</source>
                <volume>10</volume>
                <fpage>508</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">19410195</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.car_n.2008.153">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Car&#x000e9;n</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abel</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kogner</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinsson</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours.</article-title>
                <source>Biochem J</source>
                <volume>416</volume>
                <fpage>153</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">18990089</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.carpenter.2012.391">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carpenter</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moss&#x000e9;</surname>
                    <given-names>YP</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Targeting ALK in neuroblastoma--preclinical and clinical advancements.</article-title>
                <source>Nat Rev Clin Oncol.</source>
                <volume>9</volume>
                <fpage>391</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22585002</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.chen.2008.971">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takita</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choi</surname>
                    <given-names>YL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kato</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohira</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanada</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soda</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kikuchi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Igarashi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakagawara</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mano</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogawa</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Oncogenic mutations of ALK kinase in neuroblastoma.</article-title>
                <source>Nature</source>
                <volume>455</volume>
                <fpage>971</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">18923524</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.debaun.1998.398">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>DeBaun</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tucker</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry.</article-title>
                <source>J Pediatr</source>
                <volume>132</volume>
                <fpage>398</fpage>
                <lpage>400</lpage>
                <pub-id pub-id-type="pmid">9544889</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.de_brouwer.2010.4353">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>De Brouwer</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Preter</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumps</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zabrocki</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porcu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Westerhout</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lakeman</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vandesompele</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoebeeck</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Maerken</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Paepe</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laureys</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schulte</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schramm</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Den Broecke</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vermeulen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Roy</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beiske</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renard</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noguera</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delattre</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janoueix-Lerosey</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kogner</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinsson</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakagawara</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohira</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caron</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eggert</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cools</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Versteeg</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Speleman</surname>
                    <given-names>F.</given-names>
                  </name>
                </person-group>
                <article-title>Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.</article-title>
                <source>Clin Cancer Res.</source>
                <year>2010</year>
                <volume>16</volume>
                <fpage>4353</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">20719933</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.de_pontual.2011.272">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>de Pontual</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kettaneh</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gordon</surname>
                    <given-names>CT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oufadem</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boddaert</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lees</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balu</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lachassinne</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petros</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mollet</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brugi&#x000e8;re</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delattre</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vekemans</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Etchevers</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lyonnet</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janoueix-Lerosey</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amiel</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Germline gain-of-function mutations of ALK disrupt central nervous system development.</article-title>
                <source>Hum Mutat.</source>
                <volume>32</volume>
                <fpage>272</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">21972109</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.eng.2008.883">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Cancer: A ringleader identified.</article-title>
                <source>Nature</source>
                <volume>455</volume>
                <fpage>883</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">18923503</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.george.2008.975">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>George</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanda</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fr&#x000f6;hling</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luther</surname>
                    <given-names>W</given-names>
                    <suffix>2nd</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahn</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>London</surname>
                    <given-names>WB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGrady</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xue</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zozulya</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregor</surname>
                    <given-names>VE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Webb</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gray</surname>
                    <given-names>NS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gilliland</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Diller</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greulich</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morris</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyerson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Look</surname>
                    <given-names>AT</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Activating mutations in ALK provide a therapeutic target in neuroblastoma.</article-title>
                <source>Nature</source>
                <volume>455</volume>
                <fpage>975</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">18923525</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.irwin.2015.225">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Irwin</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>JR</given-names>
                  </name>
                </person-group>
                <article-title>Neuroblastoma: paradigm for precision medicine.</article-title>
                <source>Pediatr Clin North Am.</source>
                <year>2015</year>
                <volume>62</volume>
                <fpage>225</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">25435121</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.janoueixlerosey.2008.967">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Janoueix-Lerosey</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lequin</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brugi&#x000e8;res</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ribeiro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Pontual</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Combaret</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raynal</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Puisieux</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schleiermacher</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pierron</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valteau-Couanet</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frebourg</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michon</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lyonnet</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amiel</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delattre</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma.</article-title>
                <source>Nature</source>
                <volume>455</volume>
                <fpage>967</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">18923523</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.liu.2012.325">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thiele</surname>
                    <given-names>CJ</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>ALK and MYCN: when two oncogenes are better than one.</article-title>
                <source>Cancer Cell.</source>
                <volume>21</volume>
                <fpage>325</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">22439928</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.morris.1994.1281">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Morris</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kirstein</surname>
                    <given-names>MN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valentine</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dittmer</surname>
                    <given-names>KG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shapiro</surname>
                    <given-names>DN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saltman</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Look</surname>
                    <given-names>AT</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin&#x02019;s lymphoma.</article-title>
                <source>Science</source>
                <volume>263</volume>
                <fpage>1281</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">8122112</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.moss_.2012">
              <mixed-citation publication-type="confproc">Moss&#x000e9; YP, Balis FM, Lim MS, Laliberte J, Voss SD, Fox E, Bagatell R, Weigel B, Adamson PC, Ingle AM, Ahern CH, Blaney S. Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study. Abstract 9500. Chicago, IL: American Society of Clinical Oncology Annual Meeting; 2012.</mixed-citation>
            </ref>
            <ref id="alk-nbs.REF.moss_.2008.930">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Moss&#x000e9;</surname>
                    <given-names>YP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laudenslager</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longo</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cole</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Attiyeh</surname>
                    <given-names>EF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laquaglia</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sennett</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lynch</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perri</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laureys</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Speleman</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hou</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hakonarson</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torkamani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schork</surname>
                    <given-names>NJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brodeur</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tonini</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rappaport</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Devoto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maris</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Identification of ALK as a major familial neuroblastoma predisposition gene.</article-title>
                <source>Nature</source>
                <volume>455</volume>
                <fpage>930</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">18724359</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.moss_.2013.472">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Moss&#x000e9;</surname>
                    <given-names>YP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lim</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voss</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilner</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruffner</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laliberte</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rolland</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balis</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maris</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weigel</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ingle</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahern</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adamson</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blaney</surname>
                    <given-names>SM</given-names>
                  </name>
                </person-group>
                <article-title>Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.</article-title>
                <source>Lancet Oncol.</source>
                <year>2013</year>
                <volume>14</volume>
                <fpage>472</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">23598171</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.palmer.2009.345">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Palmer</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vernersson</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grabbe</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hallberg</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Anaplastic lymphoma kinase: signalling in development and disease.</article-title>
                <source>Biochem J</source>
                <volume>420</volume>
                <fpage>345</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">19459784</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.park.2008.97">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eggert</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caron</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Neuroblastoma: biology, prognosis, and treatment.</article-title>
                <source>Pediatr Clin North Am</source>
                <volume>55</volume>
                <fpage>97</fpage>
                <lpage>120</lpage>
                <pub-id pub-id-type="pmid">18242317</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.schilling.2002.1047">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schilling</surname>
                    <given-names>FH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spix</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berthold</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erttmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fehse</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hero</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klein</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sander</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwarz</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Treuner</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zorn</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michaelis</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Neuroblastoma screening at one year of age.</article-title>
                <source>N Engl J Med</source>
                <volume>346</volume>
                <fpage>1047</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">11932471</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.soda.2007.561">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Soda</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choi</surname>
                    <given-names>YL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Enomoto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takada</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamashita</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishikawa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujiwara</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watanabe</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurashina</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hatanaka</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bando</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohno</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishikawa</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aburatani</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Niki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sohara</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sugiyama</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mano</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.</article-title>
                <source>Nature.</source>
                <volume>448</volume>
                <fpage>561</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">17625570</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.wood.2009">
              <mixed-citation publication-type="confproc">Wood AC, Laudenslager EA, Haglund EA, Attiyeh EF, Pawel B, Courtright J, Plegaria J, Christensen JG, Maris JM, Mosse YP. Inhibition of ALK mutated neuroblastomas by the selective inhibitor PF-02341066. Abstract 10008b. Orlando, FL: American Society of Clinical Oncology Annual Meeting; 2009.</mixed-citation>
            </ref>
            <ref id="alk-nbs.REF.woods.2002.1041">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Woods</surname>
                    <given-names>WG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gao</surname>
                    <given-names>RN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shuster</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robison</surname>
                    <given-names>LL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernstein</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weitzman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bunin</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brossard</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dougherty</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuchman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lemieux</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Screening of infants and mortality due to neuroblastoma.</article-title>
                <source>N Engl J Med</source>
                <volume>346</volume>
                <fpage>1041</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">11932470</pub-id>
              </element-citation>
            </ref>
            <ref id="alk-nbs.REF.yeh.2008.279">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yeh</surname>
                    <given-names>IT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenci</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Qin</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buddavarapu</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ligon</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leteurtre</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Do Cao</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cardot-Bauters</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pigny</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dahia</surname>
                    <given-names>PL</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>A germline mutation of the KIF1B beta gene on 1p36 in a family with neural and nonneural tumors.</article-title>
                <source>Hum Genet.</source>
                <volume>124</volume>
                <fpage>279</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">18726616</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="alk-nbs.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="alk-nbs.Author_History">
          <title>Author History</title>
          <p>Emily G Greengard, MD (2015-present)Rebecca H Johnson, MD; Seattle Children&#x02019;s Hospital (2009-2015)Julie R Park, MD (2009-present)</p>
        </sec>
        <sec id="alk-nbs.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>9 April 2015 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>9 May 2013 (cd) Revision: <italic toggle="yes">ALK</italic> sequence analysis available clinically</p>
            </list-item>
            <list-item>
              <p>27 September 2012 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>5 January 2010 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>14 August 2009 (rhj) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
